Contents

Preface 1 XiII
Preface 2 XV
A view from Esteve XIX
Dedication and Acknowledgements XXI
List of Contributors XXIII
Glossary XXIX

VOLUME 1

1 Depressive Disorders 1

1.1 Introductory and Basic Aspects 3

Neurobiology of Mood Disorders

Luz Romero, Ana Montero, Begoña Fernández and José M. Vela

1.1.1 Definition of mood disorders, impact on a global scale and unmet needs 3
1.1.2 Causes and associations in mood disorders: genetics and pharmaco-
genetics 10
1.1.3 Pathogenesis of mood disorders 14
1.1.4 Concluding remarks 33

References 35

1.2 Clinics 51

Clinical Aspects of Depressive Disorders

Rosario Pérez-Egea, Víctor Pérez, Dolors Puigdemont and Enric Alvarez

1.2.1 Introduction 51
1.2.2 Classification 52
1.2.3 Epidemiology 61
1.2.4 Physiopathology 63
1.2.5 Treatment of affective disorders 68

References 104
1.3 Pharmacology

*Pharmacotherapy of Depression*

Begoña Fernández, Luz Romero and Ana Montero

11.3.1 Introduction

1.3.2 Current antidepressant treatments

1.3.3 New strategies for antidepressant treatments

1.3.4 Concluding remarks

References

1.4 Experimental Research

*Modeling Human Depression by Animal Models*

Ana Montero, Begoña Fernández and Luz Romero

1.4.1 Introduction

1.4.2 Types of validity

1.4.3 Animal models of depression

1.4.4 Some concluding remarks

References

1.5 Chemistry

*Marketed Drugs and Drugs in Development*

Jörg Holenz, José Luis Díaz and Helmut Buschmann

1.5.1 Summary of drug classes

1.5.2 Tricyclic and tetracyclic antidepressants

1.5.3 Serotonergic agents

1.5.4 Noradrenaline reuptake inhibitors

1.5.5 Monoamine oxidase inhibitors

1.5.6 Miscellaneous agents

1.5.7 Compounds launched in single countries

1.5.8 New opportunities for marketed drugs

1.5.9 Summary of antidepressants in development

References
2 Schizophrenia and Other Psychoses

2.1 Introductory and Basic Aspects

Current Status and Challenges in Schizophrenia Research
Francesc Artigas

2.1.1 Introduction
2.1.2 Clinical diagnosis and assessment of schizophrenia
2.1.3 Epidemiology
2.1.4 Course of schizophrenia
2.1.5 Brain pathology in schizophrenia
2.1.6 Pathogenesis and pathophysiology of schizophrenia
2.1.7 Concluding remarks
References

2.2 Clinics

Schizophrenia: A Clinical Review
Salvador Ros and Francisco Javier Arranz

2.2.1 Introduction
2.2.2 Background
2.2.3 Epidemiology
2.2.4 General semiology
2.2.5 Positive symptoms in schizophrenia
2.2.6 Negative symptoms in schizophrenia
2.2.7 Cognitive alterations in schizophrenia
2.2.8 Characteristics of cognitive deterioration in schizophrenia
2.2.9 Methods to evaluate cognitive deterioration in schizophrenia
2.2.10 Affective symptoms in schizophrenia
2.2.11 Schizophrenia and suicide
2.2.12 Onset and states
2.2.13 Etiopathogeny
2.2.14 Prognosis
2.2.15 Schizophrenia therapy
References
2.3 Pharmacology  
*Pharmacotherapy of Schizophrenia*  
Analía Bortolozzi, Llorenç Díaz-Mataix and Francesc Artigas  

2.3.1 Antipsychotic drugs: introduction  
2.3.2 Atypical Antipsychotics: introduction  
2.3.3 Other major investigational approaches  
2.3.4 Concluding remarks: challenges in drug discovery  
References  

2.4 Experimental Research  
*Modeling schizophrenia in experimental animals*  
Pau Celada, Anna Castañé, Albert Adell and Francesc Artigas  

2.4.1 Introduction  
2.4.2 Neurophysiology of schizophrenia  
2.4.3 Pharmacological models of schizophrenia  
2.4.4 Neurodevelopmental models  
2.4.5 Genetic models  
2.4.6 Other animal models  
2.4.7 Concluding remarks  
References  

2.5 Chemistry  
*Marketed Drugs and Drugs in Development*  
Antonio Párraga, Jörg Holenz and Helmut Buschmann  

2.5.1 Summary of drug classes  
2.5.2 Typical antipsychotics  
2.5.3 Atypical antipsychotics  
2.5.4 Drugs in development  
References
3 Anxiety

3.1 Introductory and Basic Aspects

3.1.1 Definition and classification of anxiety disorders
Francisca López-Ríos, Serafín Gómez-Martín and Antonio Molina-Moreno
References

3.1.2 Epidemiology of anxiety disorders
Flor Zaldívar-Basurto and José M. García-Montes
References

3.1.3 Etiology of Anxiety
Margarita Moreno, Ginesa López-Crespo and Pilar Flores
References

3.1.4 Anxiety disorders and drug abuse
Diana Cardona-Mena, Margarita Moreno and Pilar Flores
References

3.1.5 Neurobiology of anxiety (I): Panic disorder, posttraumatic stress disorder, social phobia and obsessive–compulsive disorder
Lola Roldán-Tapia, Ginesa López-Crespo, Francisco Antonio Nieto-Escámez and Diana Cardona-Mena
References

3.1.6 Neurobiology of anxiety (II): Childhood anxiety, generalized anxiety disorder and mixed anxiety–depressive disorder
Francisco Antonio Nieto-Escámez, Ginesa López-Crespo, Lola Roldán-Tapia and Fernando Cañadas-Pérez
References

3.1.7 Consequences of anxiety on memory processes (I): Introductory and clinical aspects
Fernando Cañadas-Pérez, Francisco Antonio Nieto-Escámez, Lola Roldán-Tapia and Ginesa López-Crespo
References

3.1.8 Consequences of anxiety on memory processes (II): Neurobiological aspects
Francisco Nieto-Escámez, Fernando Cañadas-Pérez, Lola Roldán-Tapia and Fernando Sánchez-Santed
References
3.2 Clinics

Clinical Aspects of Anxiety
Blanca Gutiérrez and Jorge Cervilla

3.2.1 Conceptual introduction 881
3.2.2 Panic disorder 882
3.2.3 Generalized anxiety disorder 885
3.2.4 Phobic anxiety disorders 888
3.2.5 Obsessive-compulsive disorder 890
3.2.6 Conclusion 892
References 893

3.3 Pharmacology

Pharmacology of Anxiety
José Manuel Baeyens

3.3.1 Introduction 895
3.3.2 Drugs used in treatment of anxiety disorders: an overview 896
3.3.3 Generalized anxiety disorder (GAD) 902
3.3.4 Social anxiety disorder (SAD) or social phobia 905
3.3.5 Simple or specific phobia 908
3.3.6 Panic disorder (PD) 908
3.3.7 Posttraumatic stress disorder (PTSD) 911
3.3.8 Obsessive-compulsive disorder (OCD) 914
References 918

3.4 Experimental Research

Modeling Human Anxiety by Animal Models
Enrique Portillo and José Miguel Vela

3.4.1 General concepts on animal models 923
3.4.2 General aspects of human anxiety 925
3.4.3 Animal anxiety 926
3.4.4 Potential issues in animal models of anxiety 937
3.4.5 Conclusions: Implication for drug discovery 940
References 942
3.5 Chemistry

Marketed Drugs and Drugs in Development
Mónica García-López, Susana Yenes, Helmut Buschmann and Antoni Torrens

3.5.1 Summary of drug classes
3.5.2 Benzodiazepines
3.5.3 Serotonergic drugs
3.5.4 GABAergic agents
3.5.5 Dopaminergic agents
3.5.6 Serotonin reuptake stimulants
3.5.7 \( \beta \)-adrenoceptor antagonists
3.5.8 Glucocorticoid receptor antagonists
3.5.9 GAT-1 inhibitors
3.5.10 Calcium channel blockers
3.5.11 No-described mechanism of action
3.5.12 Drugs in development

References

4 Attention Deficit and Hyperactivity Disorders

4.1 Introductory and Basic Aspects

Neurobiological aspects of Attention Deficit and Hyperactivity Disorders
Javier Burgueño, Rafael Franco and Francisco Ciruela

4.1.1 Definition and introductory clues
4.1.2 Etiology of ADHD

References

4.2 Clinics

Attention Deficit Hyperactivity Disorder: Clinical and Therapeutic Facts
Francisco Javier Arranz and Salvador Ros

4.2.1 Introduction
4.2.2 Epidemiology
4.2.3 Etiology
4.2.4 Pathophysiology
4.2.5 Clinical features

References
4.3 Pharmacology  
Pharmacology: Targets of Drug Action  
Francisco Ciruela, Rafael Franco and Javier Burgueño  
- 4.3.1 Neurobiological evidence for ADHD as an organic phenomenon  
- 4.3.2 Neurochemistry of ADHD: Neurotransmitter imbalance  
References  

4.4 Chemistry  
Marketed Drugs and Drugs in Development  
Jörg Holenz, José Luis Díaz and Helmut Buschmann  
- 4.4.1 Summary of drug classes  
- 4.4.2 Drugs in development  
References  

Index